Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT00920855. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to assess the safety and tolerability of bendamustine as combination therapy with bortezomib for patients with relapsed/refractory multiple myeloma (MM).
Study identification
- NCT ID
- NCT00920855
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2009 (Type not available)
- Primary completion
- Jul 2011 (Actual)
- Completion
- Dec 2011 (Actual)
- Last update posted
- Oct 4, 2012
2009 – 2011
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pacific Oncololgy & Hematology | Encinitas | California | — | — |
| Capitol Hematology Oncology | Roseville | California | — | — |
| University Of California, San Diego | San Diego | California | — | — |
| James R. Berenson, M.D., Inc. | West Hollywood | California | — | — |
| George Washington University | Washington D.C. | District of Columbia | — | — |
| Northshore University Health System | Evanston | Illinois | — | — |
| Alivin & Lois Lapidus Cancer Institute | Baltimore | Maryland | — | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | — | — |
| Sophia Gordon Cancer Center at Lahey Clinic | Burlington | Massachusetts | — | — |
| Geisinger Medical Center | Danville | Pennsylvania | — | — |
| Charleston Hematology Oncology, PA | Charleston | South Carolina | — | — |
| Family Cancer Center, PLLC | Collierville | Tennessee | — | — |
| Fairfax Northern Virginia Hematology Oncology | Fairfax | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00920855, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 4, 2012 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00920855 live on ClinicalTrials.gov.